High-dose atorvastatin reloading before percutaneous coronary intervention increased circulating endothelial progenitor cells and reduced inflammatory cytokine expression during the perioperative period
Related Experiment Video
Updated: May 4, 2026

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia
Published on: September 22, 2020
Honghua Ye1, Fuwei He, Xiaohong Fei
11Department of Cardiology, Ningbo First Hospital, the Affiliated Hospital of School of Medcine of Ningbo University, Ningbo, China.
Insights
High-dose atorvastatin reloading before percutaneous coronary intervention (PCI) significantly increased early endothelial progenitor cell (EPC) circulation. This approach also reduced inflammatory markers and myocardial injury post-PCI in patients with stable angina.
Area of Science:
- Cardiology
- Vascular Biology
- Pharmacology
Background:
- Patients with stable angina pectoris often undergo percutaneous coronary intervention (PCI).
- Long-term statin therapy is common in these patients.
- Endothelial progenitor cells (EPCs) play a role in vascular repair.
Purpose of the Study:
- To investigate the effects of atorvastatin reloading on EPC count and inflammatory markers after PCI.
- To assess the impact on myocardial injury in patients with prior long-term statin treatment.
Main Methods:
- Patients were divided into three groups: high-dose atorvastatin (80mg pre-PCI), lower-dose atorvastatin (40mg pre-PCI), and control.
- EPCs (CD45-/133+/34+, CD45-/CD34+/KDR+, CD45-/CD144+/KDR+) were quantified by flow cytometry.
- Serum levels of sICAM-1, hCRP, and TnI were measured before and after PCI.
Main Results:
- High-dose atorvastatin significantly increased circulating early EPCs (CD45-/133+/34+ and CD45-/CD34+/KDR+) post-PCI compared to baseline.
- Control group showed significant increases in sICAM-1 and hCRP post-PCI, which were not observed in atorvastatin groups.
- The rise in troponin-I (TnI) post-PCI was significantly lower in both atorvastatin reloading groups compared to the control group.
Conclusions:
- High-dose atorvastatin administration before PCI promotes early EPC circulation.
- Atorvastatin reloading reduces postoperative inflammatory responses (sICAM-1, hCRP).
- Statin reloading is associated with less myocardial injury (TnI elevation) after PCI.
Objective:
We investigated atorvastatin reloading effects on endothelial progenitor cell (EPC) count and inflammatory cytokine expression after percutaneous coronary intervention (PCI) in patients with stable angina pectoris who had previously received long-term statin treatments.
Methods:
Patients with stable angina pectoris were treated with 80 mg atorvastatin 12 hours and 40 mg atorvastatin 2 hours before coronary angioplasty (n = 15) or preoperatively with 40 mg/d atorvastatin for 7 days (n = 15) or did not receive atorvastatin (n = 15). CD45-/133+/34+, CD45-/CD34+/kinase insert domain receptor (KDR)+, and CD45-/CD144+/KDR+ EPCs in the peripheral blood were determined by flow cytometry 1 hour before as well as 1 hour, 6 hours, and 24 hours after PCI. Soluble intercellular adhesion molecule 1 (sICAM-1), hypersensitive C-reactive protein (hCRP), and troponin-I (TnI) serum concentrations were analyzed immediately prior to and 24 hours after PCI.
Results:
In the 40mg Atorvastatin and control groups, none of the analyzed EPC blood concentrations changed significantly from 1h before operation to 1h and 6 h postoperative values. In contrast, the number of circulating early differentiation stage EPCs CD45-/133+/34+ and CD45-/CD34+/ KDR+ raised significantly from 1 h preoperative values (57.3±9.3; 57.3 ± 10.7) to 1 h postoperative ((74.4 ± 11.4; 78.8 ± 16.2), (p < 0.05)) and 6 h postoperative ((93 ± 16.9; 99.7 ± 11.9), (p < 0.05)) concentrations after coronary angioplasty in the 80mg Atorvastatin medication patients. In the control group, the sICAM-1 (174.55 ± 38.91 vs 204.11 ± 58.24) and hCRP (1.89 ± 1.93 vs 9.0 ± 11.1) serum concentrations at 24 hours after PCI were significantly elevated (P < .05) compared to preoperative values, whereas the increases in the 2 groups treated with atorvastatin were not significant. In addition, the rise in serum TnI concentration level from pre- to postoperative in the 80-mg (0.02 ± 0.02 vs 0.09 ± 0.08) and the 40-mg (0.01 ± 0.03 vs 1.2 ± 2.59) reloading groups was less than that of the controls (0.01 ± 0.02 vs 1.75 ± 3.09) (p < 0.05).
Conclusion:
Our results suggested that high-dose atorvastatin application before PCI triggered early EPC circulation. Furthermore, postoperative inflammatory cytokine sICAM-1 as well as hCRP serum levels were reduced, while postinterventional myocardial injury marker TnI elevations were inversely correlated with statin reloadings.
Related Concept Videos
Atherosclerosis III: Management
Coronary Artery Disease V: Interprofessional Care
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Acute Coronary Syndrome IV: Interprofessional Care
Peripheral Artery Disease III: Interprofessional Care
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

